Food Entrepreneur PARIS — Spore.Bio has raised $23 million in a Series A funding, led by European venture capital firm Singular, bringing its total funding to $31.3 million. Spore.Bio is a technology startup that develops artificial intelligence (AI) technology targeted at microbiology testing.

Spore.Bio raised $8 million in a pre-seed funding round in 2024 to focus its efforts on R&D to help deploy prototypes in processing plants and bring its technology to the United States.

Following the Series A round, the company said it plans to now focus on scaling up its industrialization process and is preparing for commercialization before the end of the year.

“AI is nice for chatbots and LLMs, but some amazing, niche applications are paving the way of deep changes in certain industries, especially science-related industries,” said Amine Raji, chief executive officer and co-founder of Spore.Bio. “We are proud of being an example of it, while having developed in only one year our proprietary AI-based technology that manages to do what existing technologies couldn’t for two centuries. We will keep on fighting to pursue our one and only goal: make every consumer product safe all around the world using our technology.”

With Spore.Bio’s technology, manufacturers are able to quickly test for contamination with the startup’s immediate, on-site solution.

The company’s device uses “advanced machine learning models” that are able to measure bacterial concentrations in food, beverages, pharmaceuticals and cosmetic products.

“Our technology combines a photonics innovation with innovative deep learning models; we take a snapshot of lots of samples of a food product, contaminated and not, and train our algorithm to recognize the microorganism signature,” Raji said. 


Enjoying this content? Learn about more disruptive startups on the Food Entrepreneur page.